Alpex Pharma

Alpex Pharma is a research-based pharmaceutical company focused on developing innovative medical products to address unmet healthcare needs. Founded in 1983, Alpex Pharma operates as a pharmaceutical company that specializes in the development and production of medical products. The company has not undergone significant pivots, nor does it have reported subsidiaries. It is headquartered in Switzerland.

In August 2007, Alpex raised CHF 10. 9 million in a Series B funding round led by BB Biotech Ventures, with participation from existing investor Signet Healthcare Partners, bringing the total amount raised to CHF 10. 9 million. The most recent deal was completed on August 22, 2007.

Alpex Pharma specializes in developing and manufacturing a wide range of pharmaceutical products aimed at meeting significant medical needs. Their offerings include therapeutics for obesity, laxatives, pain management solutions, antidotes for poisonings, and treatments for chronic pain and respiratory issues. Their products cater to healthcare providers, hospitals, and pharmacies and are marketed in Europe, North America, and select regions in Asia and South America. Alpex Pharma's revenue generation is supported through direct sales and partnerships with healthcare providers and distributors.

The company earns revenue primarily from its pharmaceutical products, including prescription medications and nutraceuticals, primarily through B2B transactions with healthcare institutions, supplemented by regulatory documentation and packaging services. Alpex Pharma plans to leverage the CHF 10. 9 million raised in its most recent funding round to support new product development and expand into new markets. The funding will facilitate the design and launch of upcoming medical products aimed at addressing unmet medical needs.

Specific markets targeted for expansion include North America and select Asian countries, with initiatives expected to roll out within the next few years.